EUDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
EUDA Health Holdings Ltd is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading far above the latest analyst price target, has no supportive news catalyst, no strong proprietary buy signal, and the near-term technical setup is stretched. Given the available data, I would avoid buying it now and would classify it as a sell/avoid for this profile.
EUDA is in a short-term bullish phase on momentum, but the setup looks extended rather than attractive for a fresh long-term entry. MACD histogram is positive and expanding, which supports upward momentum. However, RSI_6 is 76.57, which indicates an overheated condition despite being labeled neutral in the source. Moving averages are converging, suggesting the trend is not cleanly accelerating. Price at 17.83 is slightly below resistance at R1 17.947 and close to a near-term ceiling, with pivot support at 15.723. The stock trend model also projects downside over the next day, week, and month, which weakens the current entry case.
No recent news catalysts were reported. The only mild positive is that momentum indicators are currently supportive, with MACD expanding above zero and price trading near resistance after a recent move higher. Post-market change was also positive at 1.90%, but this is not enough to outweigh the lack of fundamental and sentiment support.
Analyst sentiment turned more cautious in valuation terms: Greenridge cut its price target sharply from $6 to $2.75, mainly due to lower Helixe bottle sales assumptions and dilution from 12.5M new shares issued in late February. There was no news in the past week, no notable hedge fund or insider accumulation, no recent congress trading, and no proprietary buy signal from AI Stock Picker or SwingMax. The modeled stock trend also points to negative returns over the next day, week, and month.
Latest quarter financials were not provided because the financial snapshot returned an error, so there is no reliable quarter-by-quarter revenue or earnings detail to assess. The only available fundamental update is indirect: the analyst model revision suggests lower expected 2026 revenue ($27.23M versus $43.05M previously) and EPS pressure from dilution, which is a negative sign for growth quality.
The latest analyst update on 2026-03-09 kept a Buy rating but cut the price target materially from $6 to $2.75. That creates a mixed Wall Street view: the rating remains positive on paper, but the drastic target reduction reflects weaker expectations for sales and earnings. In practical terms, pros still have a Buy label, but the cons view is much stronger because of reduced revenue assumptions and dilution. For a long-term beginner, this is not a compelling endorsement at the current price.
